Eupraxia
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2198 Yukon St, Vancouver, British Columb...Phone Number
(250) 590-3968Website
www.eupraxiapharma.comRevenue
-Stock Symbol
EPRXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About Eupraxia
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc.Explore more
Eupraxia Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eupraxia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Eupraxia has new funding data
Earning: See what the market has to say on Eupraxia recently announced quarterly report
Check if Eupraxia has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Eupraxia is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Eupraxia
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Eupraxia had a recent Job posting/layoffs
Product Launch: Get notified when Eupraxia launches new products
Eupraxia, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Eupraxia
Compare insights from companies similar to Eupraxia, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Eupraxia is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Eupraxia is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Eupraxia.
Eupraxia financials insights
Gather financial insights about Eupraxia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$8M
2024
Share Placement
$62M
Eupraxia Tech Stack
A closer look at the technologies used by Eupraxia
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Promotion
Executive Move
Executive Moves, Promotion
Project
Eupraxia has attributed the delayed peak in symptom improvement observed in Phase IIa from 2 weeks to 6 months to the drug's dual mechanism of reducing inflammation and reversing fibrosis.
Medical Research, Pharmaceuticals
Project
Pharmaceuticals, Clinical Operations
Top Business Services Companies
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Eupraxia
Sign Up For FreeTo access detailed company insights
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-... Read More
